OnlineBusinessBureau.com
We are not the Better Business Bureau. We're better!
 
   About Us
   Our Ratings
   Look up a Company
   File a Complaint
   Complaint Resolution
     Center
   Resources
   Membership - Join Now!
   Member Login
   Testimonials
   Contact Us

1,847,209 companies
in our database.

Join our weekly
Consumer Fraud
Alert Newsletter



Our members proudly
display this seal!

News Releases

Back

Blueprint Medicines - Product Pipeline Review - 2014 - New Market Study Published

Global Markets Direct's, 'Blueprint Medicines - Product Pipeline Review - 2014', provides an overview of the Blueprint Medicines's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Blueprint Medicines's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Full Report Details at
 - http://www.fastmr.com/prod/933134_blueprint_medicines_product_pipeline_review_2014.aspx?afid=101

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

 * The report provides brief overview of Blueprint Medicines including business description, key information and facts, and its locations and subsidiaries
 * The report reviews current pipeline of Blueprint Medicines's human therapeutic division and enlists all their major and minor projects
 * The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
 * Special feature on out-licensed and partnered product portfolio
 * The report summarizes all the dormant and discontinued pipeline projects
 * Latest company statement
 * Latest news and deals relating to the Blueprint Medicines's pipeline products

Reasons to Get this Report

 * Evaluate Blueprint Medicines's strategic position with total access to detailed information on its product pipeline
 * Assess the growth potential of Blueprint Medicines in its therapy areas of focus
 * Identify new drug targets and therapeutic classes in the Blueprint Medicines's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
 * Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
 * Develop strategic initiatives by understanding the focus areas of Blueprint Medicines and exploit collaboration and partnership opportunities
 * Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 * Plan mergers and acquisitions effectively by identifying the most promising pipeline of Blueprint Medicines
 * Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 * Explore the dormant and discontinued projects of Blueprint Medicines and identify potential opportunities in those areas
 * Avoid Intellectual Property Rights related issues

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Blueprint Medicines Snapshot
Blueprint Medicines Overview
Key Information
Key Facts
Blueprint Medicines - Research and Development Overview
Key Therapeutic Areas
Blueprint Medicines - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Blueprint Medicines - Pipeline Products Glance
Blueprint Medicines - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Blueprint Medicines - Drug Profiles
BLU-554
Product Description
Mechanism of Action
R&D Progress
BLU-9931
Product Description
Mechanism of Action
R&D Progress
BLU-285
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Kinase for Oncology
Product Description
Mechanism of Action
R&D Progress
Blueprint Medicines - Pipeline Analysis
Blueprint Medicines - Pipeline Products by Target
Blueprint Medicines - Pipeline Products by Molecule Type
Blueprint Medicines - Pipeline Products by Mechanism of Action
Blueprint Medicines - Recent Pipeline Updates
Blueprint Medicines - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Blueprint Medicines, Key Information
Blueprint Medicines, Key Facts
Blueprint Medicines - Pipeline by Indication, 2014
Blueprint Medicines - Pipeline by Stage of Development, 2014
Blueprint Medicines - Monotherapy Products in Pipeline, 2014
Blueprint Medicines - Preclinical, 2014
Blueprint Medicines - Discovery, 2014
Blueprint Medicines - Pipeline by Target, 2014
Blueprint Medicines - Pipeline by Molecule Type, 2014
Blueprint Medicines - Pipeline Products by Mechanism of Action, 2014
Blueprint Medicines - Recent Pipeline Updates, 2014

List of Figures
Blueprint Medicines - Pipeline by Top 10 Indication, 2014
Blueprint Medicines - Pipeline by Stage of Development, 2014
Blueprint Medicines - Monotherapy Products in Pipeline, 2014
Blueprint Medicines - Pipeline by Top 10 Target, 2014

Full Table of Contents is available at:
-- http://www.fastmr.com/prod/933134_blueprint_medicines_product_pipeline_review_2014.aspx?dt=t&afid=101

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available.  Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

 


Credit Secrets Bible

Get Paid for
Doing Surveys





The Online Business Bureau -- 21441 Pacific Boulevard -- Suite 200 -- Sterling, VA 20166 -- 202-558-5282
News Releases |  News Articles |  Financial Calculators |  Contact Us |  Privacy Policy | Terms of Use & Legal Notice
Copyright © 2018 Online Business Bureau, L. C.. All Rights Reserved.
We are not affiliated with the Council of Better Business Bureaus, Inc.